中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 10
Oct.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(10): 2444-2447

Advances in direct-acting antiviral therapy for liver transplant recipients with HCV-related hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2021.10.039

  • Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China

Research funding:

National Natural Science Foundation of China (81970519)

  • Received Date: 2021-03-24
  • Accepted Date: 2021-04-29
  • Published Date: 2021-10-20
    Abstract
  • The launch of direct-acting antiviral agents is a milestone in the treatment of hepatitis C, but further studies are needed to explore its specific timing and effectiveness in liver transplantation for HCV-related hepatocellular carcinoma (HCC). This article summarizes related guidelines, consensus statements, and recommendations in China and globally and the advantages of different treatment timing strategies. Furthermore, a retrospective analysis of related studies is performed to investigate the controversial topic of the impact of direct-acting antiviral agents on the recurrence rate of HCV-related HCC after liver transplantation, and it is pointed that direct-acting antiviral agents can reduce the risk of HCC recurrence in liver transplant recipients with HCV-related HCC. The selection of treatment timing should consider various factors such as liver function, waiting time for donors, and utilization of HCV-positive organs.

     

    • FullText(HTML)
  • loading
    • References(27)
  • [1]
    REIG M, MARIÑO Z, PERELLÓ C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy[J]. J Hepatol, 2016, 65(4): 719-726. DOI: 10.1016/j.jhep.2016.04.008.
    [2]
    de MARTEL C, GEORGES D, BRAY F, et al. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis[J]. Lancet Glob Health, 2020, 8(2): e180-e190. DOI: 10.1016/S2214-109X(19)30488-7.
    [3]
    HUESING-KABAR A, DOHNA CZ, HEINZOW H, et al. Risk factors for allograft failure in liver transplant recipients[J]. Z Gastroenterol, 2018, 56(7): 745-751. DOI: 10.1055/s-0043-125225.
    [4]
    FORMAN LM, LEWIS JD, BERLIN JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation[J]. Gastroenterology, 2002, 122(4): 889-896. DOI: 10.1053/gast.2002.32418.
    [5]
    FERRARESE A, ZANETTO A, GAMBATO M, et al. Liver transplantation for viral hepatitis in 2015[J]. World J Gastroenterol, 2016, 22(4): 1570-1581. DOI: 10.3748/wjg.v22.i4.1570.
    [6]
    CURRY MP, FORNS X, CHUNG RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: An open-label study[J]. Gastroenterology, 2015, 148(1): 100-107. e1. DOI: 10.1053/j.gastro.2014.09.023.
    [7]
    MANNS M, SAMUEL D, GANE EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: A multicentre, open-label, randomised, phase 2 trial[J]. Lancet Infect Dis, 2016, 16(6): 685-697. DOI: 10.1016/S1473-3099(16)00052-9.
    [8]
    CHARLTON M, EVERSON GT, FLAMM SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease[J]. Gastroenterology, 2015, 149(3): 649-659. DOI: 10.1053/j.gastro.2015.05.010.
    [9]
    BELLI LS, BERENGUER M, CORTESI PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study[J]. J Hepatol, 2016, 65(3): 524-531. DOI: 10.1016/j.jhep.2016.05.010.
    [10]
    PASCASIO JM, VINAIXA C, FERRER MT, et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation[J]. J Hepatol, 2017, 67(6): 1168-1176. DOI: 10.1016/j.jhep.2017.08.008.
    [11]
    BESTE LA, GREEN PK, BERRY K, et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma[J]. J Hepatol, 2017, 67(1): 32-39. DOI: 10.1016/j.jhep.2017.02.027.
    [12]
    PRENNER SB, VANWAGNER LB, FLAMM SL, et al. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals[J]. J Hepatol, 2017, 66(6): 1173-1181. DOI: 10.1016/j.jhep.2017.01.020.
    [13]
    SINGAL AG, LIM JK, KANWAL F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: Expert review[J]. Gastroenterology, 2019, 156(8): 2149-2157. DOI: 10.1053/j.gastro.2019.02.046.
    [14]
    TERRAULT NA, MCCAUGHAN GW, CURRY MP, et al. International liver transplantation society consensus statement on hepatitis C management in liver transplant candidates[J]. Transplantation, 2017, 101(5): 945-955. DOI: 10.1097/TP.0000000000001708.
    [15]
    European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018[J]. J Hepatol, 2018, 69(2): 461-511. DOI: 10.1016/j.jhep.2018.11.004.
    [16]
    Organ Transplantation Branch, Chinese Medical Doctor Association, Chinese Society of Organ Transplantation, Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma (2018)[J]. J Clin Hepatol, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.

    中国医师协会器官移植医师分会, 中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.
    [17]
    Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2019 version)[J]. J Clin Hepatol, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
    [18]
    YANG JD, AQEL BA, PUNGPAPONG S, et al. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma[J]. J Hepatol, 2016, 65(4): 859-860. DOI: 10.1016/j.jhep.2016.06.023.
    [19]
    ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts[J]. J Hepatol, 2016, 65(4): 734-740. DOI: 10.1016/j.jhep.2016.05.045.
    [20]
    ZANETTO A, SHALABY S, VITALE A. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals[J]. Liver Int, 2017, 23(9): 1103-1112. DOI: 10.1111/liv.13422
    [21]
    ZANAGA LP, SANTOS AG, ATAÍDE EC, et al. Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center[J]. Braz J Med Biol Res, 2019, 52(8): e8519. DOI: 10.1590/1414-431X20198519.
    [22]
    BIELEN R, MORENO C, van VLIERBERGHE H, et al. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience[J]. J Viral Hepat, 2017, 24(11): 976-981. DOI: 10.1111/jvh.12726.
    [23]
    EMAMAULLEE JA, BRAL M, MEEBERG G. HCV eradication with direct-acting antivirals does not impact HCC progression on the waiting list or HCC recurrence after liver transplantation[J]. Can J Gastroenterol Hepatol, 2019, 2019: 2509059. DOI: 10.1155/2019/2509059.
    [24]
    JAIN A, MILLER D, SCHREIBMAN I, et al. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?[J]. Hepatol Int, 2019, 13(2): 190-198. DOI: 10.1007/s12072-019-09930-x.
    [25]
    GORGEN A, GALVIN Z, HUANG AC, et al. The impact of direct-acting antivirals on overall mortality and tumoral recurrence in patients with hepatocellular carcinoma listed for liver transplantation: An international multicenter study[J]. Transplantation, 2020, 104(10): 2087-2096. DOI: 10.1097/TP.0000000000003115.
    [26]
    ADHOUTE X, PENARANDA G, RAOUL JL, et al. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: A case-control study[J]. Eur J Gastroenterol Hepatol, 2018, 30(4): 368-375. DOI: 10.1097/MEG.0000000000001082.
    [27]
    DONATO MF, INVERNIZZI F, ROSSI G, et al. Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence[J]. J Hepatol, 2017, 67(6): 1355-1356. DOI: 10.1016/j.jhep.2017.07.026.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (457) PDF downloads(49) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return